JP2023520771A5 - - Google Patents

Info

Publication number
JP2023520771A5
JP2023520771A5 JP2022558137A JP2022558137A JP2023520771A5 JP 2023520771 A5 JP2023520771 A5 JP 2023520771A5 JP 2022558137 A JP2022558137 A JP 2022558137A JP 2022558137 A JP2022558137 A JP 2022558137A JP 2023520771 A5 JP2023520771 A5 JP 2023520771A5
Authority
JP
Japan
Prior art keywords
antigen
administered
antibody
binding fragment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024127 external-priority patent/WO2021195362A1/en
Publication of JP2023520771A publication Critical patent/JP2023520771A/ja
Publication of JP2023520771A5 publication Critical patent/JP2023520771A5/ja
Pending legal-status Critical Current

Links

JP2022558137A 2020-03-26 2021-03-25 多発性骨髄腫を処置する方法 Pending JP2023520771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000229P 2020-03-26 2020-03-26
US63/000,229 2020-03-26
PCT/US2021/024127 WO2021195362A1 (en) 2020-03-26 2021-03-25 Methods of treating multiple myeloma

Publications (2)

Publication Number Publication Date
JP2023520771A JP2023520771A (ja) 2023-05-19
JP2023520771A5 true JP2023520771A5 (cg-RX-API-DMAC7.html) 2024-04-04

Family

ID=75540019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558137A Pending JP2023520771A (ja) 2020-03-26 2021-03-25 多発性骨髄腫を処置する方法

Country Status (12)

Country Link
US (1) US20230118517A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126952A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520771A (cg-RX-API-DMAC7.html)
KR (1) KR20230005163A (cg-RX-API-DMAC7.html)
CN (1) CN115698069A (cg-RX-API-DMAC7.html)
AU (1) AU2021244215A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018987A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176257A1 (cg-RX-API-DMAC7.html)
IL (1) IL296723A (cg-RX-API-DMAC7.html)
MX (1) MX2022011800A (cg-RX-API-DMAC7.html)
TW (1) TW202202170A (cg-RX-API-DMAC7.html)
WO (1) WO2021195362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
MX2024005453A (es) * 2021-11-05 2024-07-22 Springworks Therapeutics Inc Composiciones y tratamientos con nirogacestat.
WO2023150627A1 (en) * 2022-02-03 2023-08-10 Predicine, Inc. Systems and methods for monitoring of cancer using minimal residual disease analysis
IL316750A (en) * 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12667555B2 (en) 2022-05-20 2026-06-30 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US662510A (en) 1899-05-20 1900-11-27 Western Electric Co Incandescent-lamp socket.
CH646696A5 (de) 1980-11-28 1984-12-14 Sandoz Ag Dibenzazepine, ihre herstellung und verwendung.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU779875B2 (en) 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
DE60112957T2 (de) 2000-11-02 2006-05-18 Merck Sharp & Dohme Ltd., Hoddesdon Sulfamide als gamma-secretase-inhibitoren
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2015120065A1 (en) 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
MA44254A (fr) * 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
US10307388B2 (en) 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11970542B2 (en) 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
BR112020023975A2 (pt) 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
US11773369B2 (en) 2018-08-03 2023-10-03 The Regents Of The University Of California Generation of human spinal cord neural stem cells
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020212914A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
ES3055762T3 (en) 2019-08-09 2026-02-16 Pfizer Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Similar Documents

Publication Publication Date Title
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2023544407A5 (cg-RX-API-DMAC7.html)
JP7160533B2 (ja) 多発性骨髄腫(mm)の処置
JP2024540054A5 (cg-RX-API-DMAC7.html)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2023505218A5 (cg-RX-API-DMAC7.html)
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2024517535A5 (cg-RX-API-DMAC7.html)
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
JP2019532970A5 (cg-RX-API-DMAC7.html)
JP2024540435A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2023542879A5 (cg-RX-API-DMAC7.html)
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2022521773A5 (cg-RX-API-DMAC7.html)
JP2022520572A5 (cg-RX-API-DMAC7.html)
JP2023506779A5 (cg-RX-API-DMAC7.html)
JP2022549218A5 (cg-RX-API-DMAC7.html)
CA3129890A1 (en) Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
JP2023550311A5 (cg-RX-API-DMAC7.html)